Valeo Pharma Stock Today
| VPHIF Stock | USD 0.05 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 69
|
Valeo Pharma is trading at 0.0469 as of the 28th of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.0469. Valeo Pharma has more than 69 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Valeo Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. The company was incorporated in 2003 and is headquartered in Kirkland, Canada. The company has 82.19 M outstanding shares. More on Valeo Pharma
Moving against Valeo Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Valeo Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Valeo Pharma [VPHIF] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 35.68 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Valeo Pharma's market, we take the total number of its shares issued and multiply it by Valeo Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Valeo Pharma classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 82.19 M outstanding shares.
Valeo Pharma has accumulated about 27.72 M in cash with (28.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Valeo Pharma Probability Of Bankruptcy
Ownership AllocationValeo Pharma shows a total of 82.19 Million outstanding shares. Valeo Pharma maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Valeo Ownership Details
Valeo Pharma Risk Profiles
| Mean Deviation | 1.5 | |||
| Standard Deviation | 6.17 | |||
| Variance | 38.04 | |||
| Risk Adjusted Performance | (0.09) |
Valeo Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Valeo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sign In To Macroaxis Now
Sign In To MacroaxisSign in to explore Macroaxis' wealth optimization platform and fintech modules |
| All Next | Launch Module |
Valeo Pharma Corporate Management
| Jean Fournier | Head Unit | Profile | |
| Steven CA | Vice CEO | Profile | |
| Kyle Steiger | VP Officer | Profile | |
| MBA MBA | VP CFO | Profile | |
| GuyPaul Allard | VP Sec | Profile | |
| Frederic Dumais | Director Relations | Profile |
Other Information on Investing in Valeo Pink Sheet
Valeo Pharma financial ratios help investors to determine whether Valeo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valeo with respect to the benefits of owning Valeo Pharma security.